As of Oct 25
| 0.00 / 0.00%|
The 1 analysts offering 12-month price forecasts for MabVax Therapeutics Holdings Inc have a median target of 18.00, with a high estimate of 18.00 and a low estimate of 18.00. The median estimate represents a +383.87% increase from the last price of 3.72.
The current consensus among 1 polled investment analysts is to Buy stock in MabVax Therapeutics Holdings Inc. This rating has held steady since October, when it was unchanged from a Move your mouse over past
months for detail
Move your mouse over a quarter or year to see how estimates have changed over time.